Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin for PSC and Biliary Atresia
NCT02137668Phase 1Recruiting
- Sponsor
- Sacramento Pediatric Gastroenterology
- Start
- Jul 2010
- Primary completion
- May 2018
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vancomycin in Primary Sclerosing Cholangitis (PSC) and biliary atresia, sponsored by Sacramento Pediatric Gastroenterology. Primary endpoint: Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia at 3 months. Started Jul 2010; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Primary Sclerosing Cholangitis (PSC)biliary atresia
Beyond the preview
Go deeper on NCT02137668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137668.